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5-Aminolevulinic acid (ALA) is a photosensitizer used in photodynamic therapy (PDT) because it causes preferential
accumulation of protoporphyrin IX (PpIX) in tumor cells, where it forms singlet oxygen upon light irradiation and
kills the tumor cells. Our previous study demonstrated that PpIX enhances generation of reactive oxygen species by
physicochemical interaction with X-rays. We investigated the effect of ALA administration with X-ray irradiation of
mouse B16-BL6 melanoma cells in vitro and in vivo. ALA facilitates PpIX accumulation in tumor cells and enhances
ROS generation in vitro. Tumor suppression significantly improved in animals treated with fractionated doses of
radiation (3 Gy × 10; total, 30 Gy) with local administration of 50 mg/kg ALA at 24 h prior to fractional irradiation.
These results suggest ALA may improve the efficacy of cancer radiotherapy by acting as a radiomediator.
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In cancer therapy, radiotherapy is preferred to surgical
resection because it is non-invasive, allowing organ
structures and functions to remain intact. Radiotherapy
damages the DNA of cancerous cells by direct or indir-
ect ionization of the atoms that make up the DNA chain.
However, tumor responses to radiation vary with repair
capacity, oxygenation, and other factors, and side effects
in normal tissues increase with the higher doses used to
kill radio-resistant tumor cells Peters et al. (1982). To in-
crease the sensitivity of the tumor site alone, many po-
tential radiosensitizers have been studied (Rotman et al.
1998). The mechanism of most radiosensitizers, except
oxygen or nitric oxide, involves inhibition of nucleic acid
synthesis, angiogenesis, DNA repair, and cell signaling,
eventually inducing apoptosis in treated cells. To control
and limit irradiation to tumor cells, sparing normal cells,
it is important to develop methods to enhance dosing
precision.
Photodynamic therapy (PDT) is used to treat certain
cancerous and pre-cancerous dermatological conditions. It
is preferred over surgical resection because it is non-
invasive, as is the case for radiotherapy. PDT, established in* Correspondence: junko-takahashi@aist.go.jp
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sensitive agents known as photosensitizers that preferen-
tially accumulate in target cells and produce energy
transfer and a local chemical effect (Ding et al. 2011). After
exposure to specific wavelengths of light, the photosensi-
tizer is excited from the ground state to the singlet state,
then undergoes type I (electron transfer) and/or type II
(energy transfer) reactions to produce reactive oxygen spe-
cies (ROS), resulting in necrosis and/or apoptosis of
exposed cells Pass (1993). The penetration depth of the
light source though tissue limits treatment to tumors on or
under the skin, or on the lining of some internal organs,
because successful use of PDT requires light activation of
photosensitizers.
Protoporphyrin IX (PpIX) were examined as a candidate
PDT photosensitizer with biological compatibility and
measured the species and amount of ROS generated by
X-ray irradiation (Takahashi & Misawa 2009). ROS detec-
tion reagents (APF and DHE) and ethanol quencher were
used in solutions containing different concentrations of
PpIX in the study. This combination of experimental con-
ditions allowed us to estimate the contribution of PpIX to
the generation of hydroxyl radical (∙OH), superoxide anion
(O2
-), and singlet oxygen (1O2). Today, 5-aminolevulinic
acid (ALA)-PDT is used to treat a variety of neoplastic
and non-neoplastic disorders to avoid the prolonged
photosensitivity caused by systemic administrationis an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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pro-drug and is absorbed and converted by the heme
biosynthetic pathway to photoactive PpIX, which accu-
mulates preferentially in rapidly dividing cells after light
exposure, without cytotoxicity. We hypothesized that
PpIX accumulation could be induced by adding exogen-
ous ALA, and through its generation of ROS by X-ray
irradiation in cancer cells, may act as a radio-mediator
of radiotherapy. This study investigated the effect of
ALA administration with X-ray irradiation of mouse
B16-BL6 melanoma cells in vitro and in vivo.
Methods and materials
Chemicals
ALA hydrochloride, methanol, perchloric acid, acetic
acid, sodium hydrogen carbonate, RPMI1680 medium,
penicillin, streptomycin, fetal bovine serum, and PBS
were purchased from Wako Chemicals (Osaka, Japan).
CellROX™ Deep Red Reagent was from Invitrogen
(Carlsbad, CA).
Cell culture
The B16-BL6 mouse melanoma cell line was supplied by
the Riken Cell Bank (Tsukuba, Japan) and cultured in
PRMI1640 (GIBCO BRL, Life Technologies, Tokyo,
Japan) containing 10% FBS (Moregate BioTech, QLD,
Australia) in a 5% CO2 humidified incubator at 37°C.
The medium was supplemented with 100 units/mL peni-
cillin and 100 μg/mL streptomycin (GIBCO).
Determination of porphyrin concentration in
cells and tissue
Porphyrin in cells or tissue samples was isolated in 1.0 N
perchloric acid and methanol (1:1 v/v) after homo-
genization and centrifugation at 3000 rpm for 10 min.
The supernatant was transferred to a tube, neutralized
with sodium hydrogen carbonate, and acidified with
acetic acid (96%). Porphyrin concentration was deter-
mined by spectrophotometry at the Soret maximum
(405 nm) and fluorescence using an excitation wave-
length of 405 nm and an emission wavelength of 630 nm
(Doss & Schmidt 1971). Presentation of tissue data per
gram-wet weight was performed as described previously.
Measurement of intracellular ROS
We performed in vitro studies to estimate the effect of
ALA and X-ray irradiation on intracellular ROS in B16-
BL6 cells. The cell-permeable CellROX™ Deep Red dye
is nonfluorescent in the reduced state; upon oxidation, it
exhibits excitation/emission maxima at 640/665 nm.
B16-BL6 cells were cultivated in 96-well plates to conflu-
ence. ALA was added 24 h before X-ray irradiation in
100 μL of culture medium at 1, 5, 10, 50, and 100 μg/
mL. Control cells were incubated without ALA. BeforeX-ray irradiation, CellROX™ Deep Red Reagent was
added at a final concentration of 10 μM. The plates were
placed 0.46 m from the x-ray generator and irradiated
for 1.0, 3.0, 5.0, and 10.0 min, corresponding to 1.0, 3.0,
5.0, and 10.0 Gy absorbed dose. After irradiation, plates
were incubated for 30 min at 37°C. The medium was re-
moved and the cells were washed with PBS. Fluores-
cence was measured on a microplate reader (Infinite
M200, TECAN).
Animal studies
The general procedure for the mouse B16-BL6 mouse
melanoma model was described previously (Jin et al. 2005).
Briefly, 6-week-old female C57BL/6 J mice purchased from
Charles River Laboratories Japan, Inc. (Yokohama, Japan)
were used for all experiments. Mice were subcutaneously
injected with B16-BL6 cells (1.3 × 105 cells) in 0.1 mL
medium without FBS or antibiotics.
Mice were randomized into 4 groups (n = 5, each
group) after implantation of B16-BL6 cells; (1) control
group; (2) ALA treatment; (3) X-ray treatment; (4) ALA
and X-ray treatment. After 3 d, mice in the X-ray and
ALA and X-ray treatment groups were irradiated with
3 Gy daily q.d. (quaque die) × 5 × 2 weeks, for a total dose
of 30 Gy. Mice in the ALA and X-ray treatment group
were administrated local ALA diluted in PBS at 50 mg/kg
bodyweight 24 h before X-ray irradiation. The mice in the
ALA treatment group received ALA at the same time.
Tumor volume, based on caliper measurements, was cal-
culated every 10 days according to the following formula:
tumor volume = the shortest diameter2 × the largest diam-
eter × 0.5 (Jin et al. 2005).
X-ray irradiation conditions
A polychromatic, diagnostic X-ray generator (KXO-15E,
Toshiba Medical Systems Corp., Tochigi, Japan) was op-
erated at a tube voltage of 100 kV and a tube current of
4 mA. In vivo study, a mouse was held tight in a plastic
holder with an opening above the tumor area. The colli-
mated X-ray beam irradiated a 24 × 24 mm area at the
tumor site, large enough to cover the entire area of the
maximum tumor. A free air ionization chamber (RAM-
TEC1500-DC300, ToyoMedic Ltd., Tokyo, Japan) was
used for dose rate measurement. The resulting dose rate
was 1.007 Gy/min at the sample stage.
Statistics
Accumulation of porphyrin in B16-BL6 cells, intracellu-
lar ROS were analyzed by two tailed Student’s t-test.
Tumor volume changes and body weight were analyzed
by one-way analysis of variance. The Tukey-Kramer
HSD test was used for post-hoc pair-wise comparison.
Differences were significant at P < 0.05.
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Results and discussion
ALA uptake kinetics of B16-BL6 melanoma cells in vitro
and in vivo
ALA that has entered the cytoplasm may enter the heme
synthesis pathway and transiently accumulate PpIX. PpIX
converted from ALA preferentially accumulates in tumors,
the accumulation depending on the kind of tumor or

















































Figure 1 Kinetics of total porphyrin levels in B16-BL6 mouse melanom
were incubated with different concentrations of ALA for 24 h. Data are givin B16-BL6 cells in vivo, porphyrin levels were examined
in vitro. Although other kinds of porphyrin were detected
by this method, PpIX is the major porphyrin in cells or
tissues (Fritsch et al. 1997). Figure 1A shows porphyrin
kinetics in B16-BL6 cells incubated with 10 μg/mL ALA.
Porphyrin levels increased with incubation time. Figure 1B
shows the porphyrin concentration in B16-BL6 cells incu-
bated with ALA for 24 h. The porphyrin concentration
was plotted as a function of ALA concentration. Porphyrin
accumulation increased with increasing ALA concentra-
tion in B16-BL6 cells after 24 h incubation in vitro.
ALA has been approved as a photosensitizer for PDT in
the USA and Europe, and its pharmacokinetics, toxicity,10 100
onc. (µg/mL)
12 16 20 24
Time (h)
a cells in vitro. A, Cells were incubated with 10 μg/mL ALA. B, Cells
en as mean ± SD (n = 4).
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He 2010). In photodynamic therapy (PDT) the photo-
sensitizer 5- ALA can be used by systemic, oral or topical
application. 5-ALA is administrated systemically at some
clinical trials on use of PDT for advance cancer (Brown
et al. 2004). After treatment with ALA, PpIX preferentially
accumulates in tumor cells; excitation by light brings PpIX
to the singlet state, which emits fluorescence upon return-
ing to the ground state. Therefore, ALA has been used for
fluorescence-guided surgery or photodynamic diagnosis
by systemic or local administration. Lofgren et al. reported
the optimal treatment time is 3–6 h post-ALA intravenous
injection of 100–200 mg/kg for rabbits in PDT, because
the porphyrin ratio between papilloma and normal skin
was highest, providing optimized efficiency without risk of
significant damage to normal skin (Lofgren et al. 1995).
We used a protocol in which ALA was administered
immediately after X-ray irradiation for convenient prep-
aration for the next irradiation; tumor porphyrin was
measured 24 h after ALA subcutaneous intratumoral
injection (50 mg/kg). Porphyrin accumulation in im-
planted B16-BL6 tumors 24 h after administration was
6.2 times higher with local than with systematic, local
administration providing efficiencies equal or surpassing
that of PDT (3.0 ± 1.4 μg per gram wet weight). This re-
port is the first trial to confirm the effect of ALA admin-
istration with X-ray and to study the story in vivo. The
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Figure 2 Intracellular ROS level viability of ALA and X-ray treatment.
concentrations of ALA and different X-ray doses in vitro. ALA was added 24
Reagent was added at a final concentration of 10 μM to the cells. After X-ray
medium was removed and the cells were washed with PBS. The resulting fluo
mean ± SD (n = 4). An asterisk indicates significant difference compared to wi
untreated control.ROS induction by ALA and X-ray irradiation in vitro
In vitro studies were performed to estimate the effect of
ALA and X-ray treatment on intracellular ROS gener-
ation in B16-BL6 cells with CellRox™ Deep Red dye.
CellROX™ Deep Red Reagent is a fluorogenic probe de-
signed to reliably measure ROS in living cells. ROS level
is expressed in reference to the non-irradiated control
plate. Figure 2 shows ALA effects on intercellular ROS
level at different X-ray doses. B16-BL6 cells were incu-
bated with ALA for 24 h before X-ray irradiation. As a
control, cells without ALA were irradiated under the
same conditions.
Intracellular ROS increased with X-ray dose and ALA
concentration (Figure 2). Student’s t-test results showed
a significant difference between the control and 1 μg/mL
ALA treatments at 10 Gy X-ray irradiation, between the
control and 50 μg/mL ALA treatments at 5 and 10 Gy
X-ray irradiation, and between the control and 100 μg/mL
ALA treatments at 1, 3, 5 and 10 Gy X-ray irradi-
ation. In this study, PpIX enhanced ROS generation
induced by X-ray irradiation in addition to those by
radiolysis.
In vivo tumor suppression by ALA and irradiation
To evaluate tumor suppression by ALA treatment with
radiotherapy in vivo, a C57BL/6 J melanoma tumor
model was used. ALA was administrated as a local dose
of 50 mg/kg 24 h before X-ray irradiation. Figure 3A
illustrates tumor growth during fractionated doses of3 Gy 5 Gy 10 Gy
1 5 10 50 10
0 0 1 5 10 50 10





Intracellular ROS level of B16-BL6 mouse melanoma cells with various
h before X-ray irradiation. Before X-ray irradiation, CellROX™ Deep Red
irradiation, plates were incubated for 30 min at 37 degree. Subsequently,
rescence was measured using a microplate reader. Data are given as


















































Figure 3 ALA potentiates B16-BL6 tumor suppression by X-ray irradiation. C57Bl/6 mice bearing B16-BL6 cells were as follows: (1) control;
(2) ALA; (3); irradiation, 10 locally fractionated doses of 3 Gy each; (4) irradiation after ALA treatment, 10 locally fractionated doses of 3 Gy each.
Data are given as means ± SD (n = 5, *P < 0.05 vs. control, **P < 0.01 vs. control). Tumor size (A) was measured daily and body weight (B) was
measured 3 times a week; curves were plotted up to day 12.
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as the ALA-only and irradiation-only groups did not
show a tumor suppression effect. However, the fractionated
doses of X-ray irradiation after ALA intratumoral injection
significantly inhibited tumor growth 8 d after treatment
initiation. ALA synergistically sensitized B16-BL6 tumors
to radiation without systemic toxicity (Figure 3B).
Although the mechanism by which PpIX induces ROS
generation after X-ray irradiation remains unclear, we
propose the following model. Under X-ray irradiation,
the ionizing photons yield primary radicals as ∙OH, ∙H,
and e-aq during water radiolysis. Scattered photons withlower energies also generate secondary electrons and
cause excitation of triplet oxygen. These energies are
transferred to PpIX and raise it to an excited state.
During de-excitation, PpIX may generate O2
- and ∙OH, as
suggested in previous study (Takahashi & Misawa 2009).
Therefore, the primary sites of action of ALA-PDT may
be restricted to the sites of PpIX production and/or accu-
mulation; many studies have described the localization
and yield of PpIX in many tumor types (Berg 2001;
Herman et al. 1997). However, these studies addressed
only tumors of the skin or within the penetration depth
of a given light source. ALA-X-ray radiotherapy enables
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organs or invasive cancers that are difficult to remove
surgically due to the large x-ray penetration depth.
Conclusions
In conclusion, ALA improved tumor suppression by
X-ray irradiation in vivo, as PpIX accumulated in tumor
cells. The X-ray dosing conditions and ALA concentra-
tions have been well characterized in PDT treatment.
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